Visceral Fat and Fatty Liver: Causes and Reversal
Visceral fat and fatty liver disease are closely linked, with excess fat stored deep in the abdominal cavity playing a central role in the development and progression of metabolic-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). Unlike subcutaneous fat, visceral fat releases fatty acids and inflammatory signals directly into the liver via the portal circulation, driving fat accumulation within liver cells. Understanding this connection is essential for recognising risk, interpreting symptoms and taking effective action to protect long-term liver and metabolic health.
Summary: Visceral fat drives fatty liver disease by flooding the liver with fatty acids and inflammatory signals via the portal circulation, promoting fat accumulation in liver cells and worsening insulin resistance.
- Visceral fat releases free fatty acids and pro-inflammatory cytokines directly into the portal circulation, making the liver particularly vulnerable to fat deposition.
- Fatty liver disease (MASLD/NAFLD) is often silent in early stages; normal liver function tests do not exclude the condition.
- A sustained body weight reduction of 7 to 10 per cent is associated with meaningful reductions in hepatic fat, with 10 per cent or more linked to improvement in liver inflammation.
- NICE NG49 recommends lifestyle modification combining dietary change, physical activity and behavioural support as the cornerstone of management.
- Non-invasive fibrosis scoring tools such as FIB-4 and transient elastography (FibroScan) are used in UK clinical practice to monitor disease progression without biopsy.
- Cardiovascular disease is the leading cause of death in people with MASLD, underscoring the importance of treating visceral fat as a whole-body metabolic problem.
Table of Contents
- What is the link between visceral fat and fatty liver disease?
- How does visceral fat build up around the liver?
- What symptoms and health risks should you watch for?
- Can you reverse fatty liver by losing visceral fat?
- Lifestyle changes recommended by NHS and NICE guidelines
- When should you see a GP about fatty liver?
- Scientific References
- Frequently Asked Questions
Primary mechanism
Visceral Fat: Excess fat stored deep in abdominal cavity, surrounding organs
Fatty Liver (MASLD/NAFLD): Fat deposition within hepatocytes driven by portal free fatty acid influx
Key risk factors
Visceral Fat: High refined carbohydrate intake, physical inactivity, chronic stress, poor sleep, genetic variants (PNPLA3, TM6SF2)
Fatty Liver (MASLD/NAFLD): Insulin resistance, visceral adiposity, alcohol, corticosteroids, hypothyroidism, PCOS
Symptoms
Visceral Fat: Often none; increased waist circumference, metabolic abnormalities
Fatty Liver (MASLD/NAFLD): Often silent; persistent fatigue, upper right abdominal discomfort, incidental finding on ultrasound
Diagnosis and monitoring
Visceral Fat: Waist circumference, abdominal imaging; BMI alone is insufficient
Fatty Liver (MASLD/NAFLD): LFTs, FIB-4 score, ELF test, FibroScan (transient elastography), abdominal ultrasound
Associated health risks
Visceral Fat: Type 2 diabetes, cardiovascular disease, hypertension, chronic kidney disease
Fatty Liver (MASLD/NAFLD): Progression to MASH, fibrosis, cirrhosis, hepatocellular carcinoma; cardiovascular disease is leading cause of death
Reversibility
Visceral Fat: Responds to caloric deficit and increased physical activity
Fatty Liver (MASLD/NAFLD): Early steatosis often reversible with 7 to 10 per cent weight loss; advanced fibrosis and cirrhosis are not fully reversible
Key lifestyle interventions (NHS/NICE)
Visceral Fat: 150 minutes moderate aerobic activity weekly, resistance training twice weekly, Mediterranean-style diet
Fatty Liver (MASLD/NAFLD): Sustained weight loss, alcohol reduction or abstinence, structured behavioural support via NHS Tier 2 or Tier 3 services
What is the link between visceral fat and fatty liver disease?
Visceral fat releases fatty acids and inflammatory cytokines directly into the portal circulation, promoting fat deposition in liver cells and worsening insulin resistance in a self-reinforcing cycle central to MASLD development.
Visceral fat is a major contributor to metabolic-associated steatotic liver disease (MASLD), the condition previously known as non-alcoholic fatty liver disease (NAFLD), a term still used in UK NICE guidance (NG49). Visceral fat releases fatty acids and inflammatory signals directly into the portal circulation that feeds the liver.[15][16] Unlike subcutaneous fat, which sits beneath the skin, visceral fat accumulates deep within the abdominal cavity, surrounding organs including the liver, pancreas and intestines. This anatomical proximity means the liver is exposed to a continuous stream of free fatty acids and pro-inflammatory cytokines, promoting fat deposition within liver cells (hepatocytes). MASLD pathogenesis is multifactorial, involving insulin resistance, genetic susceptibility and de novo lipogenesis alongside visceral adiposity.[1][17]
The relationship is bidirectional and self-reinforcing. As visceral fat increases, insulin resistance tends to worsen, causing the liver to produce more fat from circulating glucose and fatty acids. At the same time, a fatty liver becomes less efficient at regulating blood glucose, which can encourage further fat storage. NICE NG49 recognises this metabolic interplay as central to the development and progression of NAFLD/MASLD.
It is important to note that fatty liver can occur in people who are not visibly overweight, and that normal liver function tests (LFTs) do not exclude the condition. Visceral fat distribution varies between individuals, and some people with a normal body mass index (BMI) can carry significant amounts of visceral fat, a pattern sometimes described as metabolically obese, normal weight. BMI alone is therefore an imperfect screening tool, and waist circumference or imaging may provide a more accurate picture of visceral fat burden.
How does visceral fat build up around the liver?
Visceral fat accumulates through sustained energy imbalance compounded by genetics, diet high in refined carbohydrates, physical inactivity, chronic stress and poor sleep, with South Asian populations at risk at lower BMI thresholds.
Visceral fat accumulates around the liver primarily through a sustained imbalance between energy intake and expenditure, compounded by hormonal, genetic and lifestyle factors. Fat distribution between subcutaneous and visceral depots varies considerably by genetics, sex and ethnicity and is not strictly sequential; some individuals preferentially accumulate visceral fat even at modest overall adiposity. Diets high in refined carbohydrates, added sugars and ultra-processed foods are associated with visceral fat accumulation, in part through their effects on insulin secretion, a hormone that promotes fat storage, though the precise mechanisms are complex and the subject of ongoing research.
Physical inactivity is an independent contributor. Skeletal muscle is a major site of glucose disposal, and reduced muscle activity is associated with higher circulating glucose and insulin levels, favouring fat deposition in visceral depots. Chronic psychological stress raises cortisol, a hormone that tends to direct fat storage towards the abdomen. Poor sleep quality and short sleep duration have also been associated with increased visceral adiposity, likely through effects on appetite-regulating hormones such as leptin and ghrelin, though evidence in this area continues to develop.
Genetic predisposition plays a role. Variants in genes such as PNPLA3 and TM6SF2 are associated with greater susceptibility to hepatic fat accumulation, meaning some individuals develop fatty liver at lower levels of visceral fat than others; these are risk-modifying factors rather than deterministic ones.[14][16] Ethnicity also influences risk: NHS and NICE guidance acknowledges that South Asian populations tend to accumulate visceral fat and develop metabolic complications at lower BMI thresholds, and UK action thresholds for metabolic risk assessment are adjusted accordingly.[8][9]
Secondary causes of fatty liver, including certain medicines (such as corticosteroids and some antipsychotics) and endocrine conditions (such as hypothyroidism and polycystic ovary syndrome), should also be considered.[1][2] Alcohol consumption can compound the effect of visceral fat on the liver, and metabolic and alcohol-related fatty liver frequently coexist. UK Chief Medical Officers advise keeping alcohol consumption to no more than 14 units per week, spread across several days, to reduce health risks; in the context of MASLD, further reduction or abstinence may be advisable and should be discussed with a clinician.[4]
What symptoms and health risks should you watch for?
Fatty liver is often symptomless early on; risks include progression to liver inflammation, fibrosis, cirrhosis and liver cancer, as well as type 2 diabetes and cardiovascular disease, the leading cause of death in MASLD.
Fatty liver disease caused by visceral fat is often entirely silent in its early stages, with most people experiencing no symptoms until significant liver damage has occurred. Normal LFTs are common and do not exclude fatty liver. When symptoms do arise, they may include:
-
Persistent fatigue that is disproportionate to activity levels
-
Mild discomfort or a dull ache in the upper right abdomen, where the liver sits
-
Unexplained weight gain, particularly around the waist
These symptoms are non-specific and shared by many conditions. Fatty liver is frequently discovered incidentally during an ultrasound or blood test performed for another reason.
The health risks associated with untreated MASLD/NAFLD are substantial. Without intervention, a proportion of people progress from simple steatosis (fat in the liver) to metabolic-associated steatohepatitis (MASH, previously known as non-alcoholic steatohepatitis or NASH), a more serious condition involving liver inflammation and cell damage. Over years to decades, MASH can lead to fibrosis (scarring), cirrhosis and, in a smaller number of cases, liver failure or hepatocellular carcinoma (liver cancer). The liver's regenerative capacity means early-stage disease is often reversible, but advanced fibrosis is not.
Beyond the liver itself, high visceral fat and MASLD are strongly associated with type 2 diabetes, cardiovascular disease, hypertension and chronic kidney disease. International guidelines, including those from the European Association for the Study of the Liver (EASL), recognise cardiovascular disease as a leading cause of death in people with NAFLD/MASLD, and cardiovascular risk assessment is recommended as part of routine management.[21][17] People with MASLD are more likely to die from cardiovascular causes than from liver-related ones, which underscores the importance of addressing visceral fat as a whole-body metabolic problem.
Can you reverse fatty liver by losing visceral fat?
Yes, losing visceral fat can reverse fatty liver, particularly in early stages; a 7 to 10 per cent weight reduction meaningfully reduces hepatic fat, while advanced fibrosis and cirrhosis cannot be fully reversed.
Losing visceral fat can reverse fatty liver disease, particularly in its earlier stages, and the evidence supporting this is substantial. Studies, including research published in Gastroenterology (Vilar-Gomez et al., 2015) and summarised in EASL guidance, consistently show that a sustained reduction in body weight of around 7 to 10 per cent is associated with meaningful reductions in hepatic fat content, and losses of 10 per cent or more are associated with improvement in liver inflammation and, in some cases, regression of early fibrosis. Because visceral fat is metabolically active and responds to caloric deficit and increased physical activity, the liver can show measurable improvement with sustained lifestyle change, though the timeline varies between individuals and depends on the method used to assess response.
The mechanism is straightforward: as visceral fat decreases, the flow of free fatty acids into the portal circulation falls, insulin sensitivity improves, and the liver is better able to export rather than accumulate fat. Liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may improve as hepatic fat resolves, though LFTs are an imperfect biomarker and can be normal even in significant disease. Non-invasive tests such as the FIB-4 score, the Enhanced Liver Fibrosis (ELF) test and transient elastography (FibroScan) provide a more reliable guide to fibrosis and are used in UK clinical practice to monitor progress.[1][2]
It is important to be realistic about the limits of reversal. Advanced fibrosis and cirrhosis involve structural changes to liver tissue that cannot be fully undone by weight loss alone, though halting further progression remains a meaningful and achievable goal. Wegovy (semaglutide 2.4 mg) is licensed in the UK for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis (F2 to F3), and resmetirom (Rezdiffra) holds a conditional UK authorisation for the same indication; readers should check the MHRA and EMC for the current position, as this is an active area of research. For people with obesity and MASLD, a GP may consider referral to a specialist weight management service. Access to NHS weight management services and any medicines used as part of a broader plan depends on local Integrated Care Board (ICB) commissioning and individual clinical eligibility. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered.
Lifestyle changes recommended by NHS and NICE guidelines
NICE NG49 recommends combined dietary improvement, at least 150 minutes of moderate aerobic activity weekly, resistance training twice weekly and behavioural support as the cornerstone of managing visceral fat and fatty liver.
NHS and NICE guidance consistently identifies sustained lifestyle modification as the cornerstone of managing both visceral fat and fatty liver disease, with no single intervention outperforming a combined approach to diet, physical activity and behaviour change. NICE guidance on overweight and obesity management (NG246) and on NAFLD/MASLD (NG49) recommends that weight management programmes address dietary quality, portion size, physical activity and psychological factors together, rather than focusing on any one element in isolation.[1][7]
Dietary recommendations include:
-
Reducing intake of ultra-processed foods, added sugars and refined carbohydrates
-
Increasing consumption of vegetables, legumes, wholegrains, lean protein and unsaturated fats (consistent with a Mediterranean-style dietary pattern, which has specific evidence in NAFLD/MASLD, as noted in EASL guidance)[22]
-
Avoiding sugary drinks, including fruit juice in large quantities
-
Limiting alcohol: UK Chief Medical Officers advise no more than 14 units per week, spread across several days; in the context of MASLD, further reduction or abstinence may be recommended by a clinician, as even modest alcohol intake can accelerate liver damage[4]
Physical activity guidance from the UK Chief Medical Officers and NHS recommends:
-
At least 150 minutes of moderate-intensity aerobic activity per week (such as brisk walking, cycling or swimming)
-
Resistance or strength training on at least two days per week, which evidence suggests can reduce visceral fat and improve metabolic markers, including independently of overall weight loss[19][20]
-
Reducing prolonged sitting, with regular movement breaks throughout the day
Behavioural support, including structured group programmes or individual counselling, significantly improves long-term adherence to lifestyle change. NHS Tier 2 and Tier 3 weight management services provide this support for eligible patients; referral is made through a GP, and availability depends on local ICB commissioning. Rapid or very low-calorie diets should only be undertaken under medical supervision, as too-rapid weight loss can paradoxically worsen liver inflammation in some individuals.
When should you see a GP about fatty liver?
See a GP if you have persistent fatigue, upper right abdominal discomfort or unexplained abdominal weight gain, especially with risk factors such as type 2 diabetes; jaundice, ascites or vomiting blood require urgent or emergency assessment.
You should see a GP if you have persistent fatigue, upper right abdominal discomfort, or unexplained weight gain around the abdomen, particularly if you also have risk factors such as type 2 diabetes, high blood pressure, raised cholesterol or a family history of liver disease. A GP can arrange blood tests including liver function tests, fasting lipid and glucose profiles, HbA1c, and a full blood count, as well as tests to help exclude other causes of liver disease such as viral hepatitis and autoimmune conditions. An abdominal ultrasound is commonly used as a first-line imaging investigation for suspected fatty liver in UK clinical practice.
NICE NG49 and BSG/BASL guidance also recommend non-invasive fibrosis risk scoring in primary care. The FIB-4 score, calculated from age, ALT, AST and platelet count, is widely used to stratify risk and guide referral decisions. An ELF test may be used where available. These scores help identify people who need specialist assessment, including transient elastography (FibroScan) to measure liver stiffness as a proxy for fibrosis, without requiring a liver biopsy in most cases.
Certain findings should prompt more urgent contact with a GP or specialist:
-
Jaundice (yellowing of the skin or whites of the eyes)
-
Swelling of the abdomen (ascites) or legs (oedema)
-
Easy bruising or prolonged bleeding
-
Confusion or difficulty thinking clearly, which can indicate hepatic encephalopathy in advanced disease
-
Vomiting blood or passing very dark or tarry stools, which require immediate assessment via 999 or attendance at an accident and emergency department
For symptoms that are concerning but not immediately life-threatening, NHS 111 can provide urgent advice outside of GP hours. Routine concerns about liver health, weight or metabolic risk are best discussed with a GP in the first instance. Early identification and intervention remain the most effective way to prevent progression to advanced liver disease, making proactive engagement with primary care an important step for anyone concerned about visceral fat and liver health.
Scientific References
- Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
- Non-alcoholic fatty liver disease (NAFLD).
- Overweight and obesity in adults.
- Alcohol consumption: advice on low risk drinking — UK Chief Medical Officers.
- UK Chief Medical Officers' physical activity guidelines.
- Physical activity guidelines for adults aged 19 to 64.
- Overweight and obesity management (NG246).
- Appendix A1: Summary of evidence from surveillance (NG246) — BMI thresholds for South Asian populations.
- Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
- Draft scope post-referral: GID-TA11477.
- Vilar-Gomez E et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology..
- Glass LM et al. Total body weight loss of ≥10% is associated with regression of fibrosis in NASH..
- Seko Y et al. Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in MASLD..
- Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes & Metabolism..
- MASLD beyond the liver: decoding the gut-genetic-metabolic nexus. Frontiers in Gastroenterology..
- A Global Perspective on MASLD: From Molecular Mechanisms to Therapeutic Strategy Innovation. Nutrients..
- Hepatic Insulin Resistance and Steatosis in MASLD: New Insights into Mechanisms and Clinical Implications. Diabetes & Metabolism Journal..
- Jayedi A et al. Aerobic Exercise and Weight Loss in Adults: A Systematic Review. JAMA Network Open..
- Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology..
- Association of the C-reactive protein-triglyceride-glucose index with MASLD and long-term all-cause and cardiovascular mortality. Cardiovascular Diabetology..
- Zelber-Sagi S et al. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease patients. Liver International..
Frequently Asked Questions
Can you have a fatty liver without being overweight?
Yes, fatty liver can occur in people with a normal BMI who carry significant visceral fat, a pattern sometimes called metabolically obese, normal weight. Waist circumference or imaging provides a more accurate assessment of visceral fat than BMI alone.
How quickly can fatty liver improve with lifestyle changes?
Measurable reductions in hepatic fat can occur within weeks to months of sustained lifestyle change, with a 7 to 10 per cent reduction in body weight associated with meaningful improvement. The timeline varies between individuals and depends on the severity of disease and the method used to assess response.
What tests does a GP use to assess fatty liver and visceral fat?
A GP can arrange liver function tests, fasting glucose, HbA1c and lipid profiles, plus an abdominal ultrasound as first-line imaging. The FIB-4 score and Enhanced Liver Fibrosis (ELF) test are used in UK primary care to assess fibrosis risk and guide referral for transient elastography (FibroScan).
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.






